Literature DB >> 14572480

Repetitive versus monomeric antigen presentation: direct visualization of antibody affinity and specificity.

Werner Baschong1, Lorenz Hasler, Markus Häner, Joerg Kistler, Ueli Aebi.   

Abstract

The concept of presenting antigens in a repetitive array to obtain high titers of specific antibodies is increasingly applied by using surface-engineered viruses or bacterial envelopes as novel vaccines. A case for this concept was made 25 years ago, when producing high-titer antisera against ordered arrays of gp23, the major capsid protein of bacteriophage T4 (Aebi et al., Proc. Natl. Acad. Sci. USA, 74 (1977) 5514-5518). In view of the current interest in this concept we thought it useful to employ this system to directly visualize the dependence of antibody affinity and specificity on antigen presentation. We compared antibodies raised against T4 polyheads, a tubular variant of the bacteriophage T4 capsid, which have gp23 hexamers arranged in a crystalline lattice (gp23(repetitive)), with those raised against the hexameric gp23 subunits (gp23(monomeric)). The labeling patterns of Fab-fragments prepared from these antibodies when bound to polyheads were determined by electron microscopy and image enhancement. Anti-gp23(repetitive) bound in a monospecific, stoichiometric fashion to the gp23 units constituting the polyhead surface. In contrast, anti-gp23(monomeric) decorated the polyhead surface randomly and with a 40-fold lower occupancy. These results concur with the difference in titers established by ELISA for the antisera against the repetitively displayed form of antigen (anti-gp23(repetitive)) and the randomly presented antigen (gp23(monomeric)), and they constitute a compelling visual documentation of the concept of repetitive antigen presentation to elicite a serotype-like immune response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14572480     DOI: 10.1016/j.jsb.2003.08.004

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  8 in total

1.  Evaluation of lumazine synthase from Bacillus anthracis as a presentation platform for polyvalent antigen display.

Authors:  Yangjie Wei; Newton Wahome; Greta VanSlyke; Neal Whitaker; Prashant Kumar; Michael L Barta; Wendy L Picking; David B Volkin; Nicholas J Mantis; C Russell Middaugh
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

Review 2.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

3.  Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation.

Authors:  M Lucrecia Alvarez; Emel Topal; Federico Martin; Guy A Cardineau
Journal:  Plant Mol Biol       Date:  2009-09-30       Impact factor: 4.076

Review 4.  Vaccine technologies: From whole organisms to rationally designed protein assemblies.

Authors:  Christopher P Karch; Peter Burkhard
Journal:  Biochem Pharmacol       Date:  2016-05-06       Impact factor: 5.858

5.  Classification of self-assembling protein nanoparticle architectures for applications in vaccine design.

Authors:  G Indelicato; P Burkhard; R Twarock
Journal:  R Soc Open Sci       Date:  2017-04-26       Impact factor: 2.963

Review 6.  Second career of a biosynthetic enzyme: Lumazine synthase as a virus-like nanoparticle in vaccine development.

Authors:  Rudolf Ladenstein; Ekaterina Morgunova
Journal:  Biotechnol Rep (Amst)       Date:  2020-07-06

Review 7.  Genetic Engineering of Bacteriophages Against Infectious Diseases.

Authors:  Yibao Chen; Himanshu Batra; Junhua Dong; Cen Chen; Venigalla B Rao; Pan Tao
Journal:  Front Microbiol       Date:  2019-05-03       Impact factor: 5.640

Review 8.  Applications of nanotechnology for immunology.

Authors:  Douglas M Smith; Jakub K Simon; James R Baker
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.